Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics (NASDAQ: PSTV) has received Fast Track designation from the FDA for its Rhenium-186 NanoLiposome (186RNL) aimed at treating leptomeningeal metastases (LM). This condition affects 5% of cancer patients, often resulting in severe health complications. The company expects to begin patient accrual for the ReSPECT-LM Phase 1 clinical trial in Q4 2021. The Fast Track status allows for accelerated communication with the FDA, potentially speeding up the development and approval process.
Plus Therapeutics (PSTV) announced a webinar on November 18, 2021, from 4:00 to 5:00 p.m. ET, discussing the ReSPECT-GBM trial data. Key opinion leaders will present findings on the safety and efficacy of Rhenium-186 NanoLiposome in treating recurrent glioblastoma. Speakers include Dr. Andrew J. Brenner, who will provide trial updates, and Dr. Toral Patel, who will discuss convection enhanced delivery in neurosurgery. The webinar allows for analyst and public Q&A. Data will also be presented at the Society for Neuro-Oncology Annual Meeting on November 19, 2021.
Plus Therapeutics (Nasdaq: PSTV) presented promising data on Rhenium-186 NanoLiposome (186RNL) at the ASTRO 2021 Annual Meeting, indicating its effectiveness in treating recurrent glioblastoma. The therapy demonstrated sustained, localized radiation treatment for over eight days, significantly reducing whole brain and body radiation exposure. Key findings include a mean radiation absorbed dose of 354.7 Gy to the tumor with minimal surrounding exposure. The data also supported the use of image monitoring for therapy delivery evaluation, highlighting the innovative delivery system of 186RNL.
Plus Therapeutics, Inc. (PSTV) reported its third-quarter financial results for 2021, highlighting significant advancements in its clinical trials, particularly the ReSPECT-GBM trial for recurrent glioblastoma. The company increased the trial dose by 40% without dose-limiting toxicities and received FDA clearance for its IND application for leptomeningeal metastases. Cash on hand rose to $21.3 million, while net loss was $3.7 million, reflecting increased R&D expenses. Plus Therapeutics plans to initiate further trials and strengthen its drug manufacturing capabilities in the upcoming months.
Plus Therapeutics (PSTV) announced FDA clearance for its Investigational New Drug (IND) application for Rhenium-186 NanoLiposome (186RNL), targeting leptomeningeal metastases (LM). Patient accrual for the Phase 1 dose escalation clinical trial, ReSPECT-LM, is expected to start in Q4 2021. The trial aims to assess the safety and efficacy of 186RNL, based on promising preclinical results showing marked tumor reduction and no significant toxicity in animal models. This represents a significant step towards innovative treatment options for patients with rare, difficult-to-treat cancers.
Plus Therapeutics (PSTV) will report its third quarter 2021 financial results on October 21, 2021, after market close. Management will host a conference call at 5:00 p.m. ET to discuss these results and provide a corporate update. The event can be accessed via live webcast, and a replay will be available on the company's website for 90 days. Plus Therapeutics focuses on developing targeted radiotherapeutics using a unique nanotechnology platform, aiming to treat rare cancers more effectively.
Plus Therapeutics (Nasdaq: PSTV) announced it will present interim data from its ReSPECT™ Phase 1 clinical trial of Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma at the Society for Neuro-Oncology Annual Meeting, scheduled for November 19, 2021. The presentation will cover the safety and feasibility of this innovative treatment. Dr. Andrew Brenner, the principal investigator, will lead the session, highlighting potential advancements in oncology therapeutics aimed at improving patient outcomes.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., President and CEO, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 4:20 p.m. ET. The presentation will provide an overview of the company's innovative, targeted radiotherapeutics aimed at rare cancers. Attendees can register for the presentation and one-on-one meetings through the Benzinga website. A replay will be available on Plus Therapeutics' Investor Relations page. The company is focused on developing nanoliposome-encapsulated drugs to enhance safety and efficacy for patients.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will present data on its investigational Rhenium-186 NanoLiposome (186RNL) for treating recurrent glioblastoma at the ASTRO 2021 Annual Meeting, scheduled for October 24-27 in Chicago. The presentation, titled "Image-guided Rhenium-186 NanoLiposome brachytherapy in the treatment of recurrent glioblastoma," will occur on October 27 at 1:00 p.m. CT. The abstract will be available online on October 22, and the poster will be accessible on the Company’s website. Plus Therapeutics focuses on targeted radiotherapeutics for rare cancers.
Plus Therapeutics (PSTV) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer and Senior Vice President, effective December 8, 2021. Dr. LaFrance brings nearly 40 years of experience in nuclear medicine and pharmaceuticals, with expertise in radiotherapeutics and drug development. His previous roles include Chief Medical Officer at Jubilant Pharma and Global Chief Medical Officer at IBA Molecular. CEO Marc Hedrick expressed confidence that Dr. LaFrance's extensive background will enhance the company's pipeline and support its long-term goals in addressing unmet medical needs in cancer treatment.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
